Results 101 to 110 of about 187,458 (237)

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019
Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation.
Yuko Ariza, Masayuki Murata, Yoshiko Ueda, Toshio Yoshizawa   +3 more
doaj   +1 more source

The Linker between SH2 and Kinase Domains Positively Regulates Catalysis of the Tec Family Kinases [PDF]

, 2007
Tec family nonreceptor tyrosine kinases are key immunological enzymes that control processes that range from T and B cell development to reorganization of the actin cytoskeleton. The full-length Tec kinases have been resistant to crystallization.
Andreotti, Amy, Andreotti, Amy, Joseph, Raji, Min, Lie   +3 more
core   +3 more sources

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Journal of Experimental Pharmacology, 2021
Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj  

Characterization of pathogenic germline mutations in human Protein Kinases [PDF]

, 2011
Background: Protein Kinases are a superfamily of proteins involved in crucial cellular processes such as cell cycle regulation and signal transduction. Accordingly, they play an important role in cancer biology. To contribute to the study of the relation
Baresic, A, Hopcroft, LEM, Izarzugaza, JMG, Martin, ACR, Orengo, CA, Valencia, A   +5 more
core   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

PLoS ONE, 2019
BackgroundPharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of ...
Sonja Hatz, Scott Spangler, Andrew Bender, Matthew Studham, Philipp Haselmayer, Alix M B Lacoste, Van C Willis, Richard L Martin, Harsha Gurulingappa, Ulrich Betz   +9 more
doaj   +1 more source

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate

eLife, 2015
Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang, Erik M Vogan, Laura M Nocka, Connor E Rosen, Julie A Zorn, Stephen C Harrison, John Kuriyan   +6 more
doaj   +1 more source